Healthcare provider profile · identity verified

Rajiv Joglekar, MD

Internal Medicine · ANDERSON, SC · NPI 1962451534

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Eliquis	Apixaban	307	15
Atorvastatin Calcium	Atorvastatin Calcium	262	29
Jardiance	Empagliflozin	235	suppressed
Furosemide	Furosemide	188	24
Levothyroxine Sodium	Levothyroxine Sodium	174	21
Losartan Potassium	Losartan Potassium	169	18
Potassium Chloride	Potassium Chloride	161	suppressed
Metformin Hcl	Metformin Hcl	154	20
Amlodipine Besylate	Amlodipine Besylate	152	22
Gabapentin	Gabapentin	149	17
Carvedilol	Carvedilol	144	18
Lisinopril	Lisinopril	112	12
Escitalopram Oxalate	Escitalopram Oxalate	110	14
Rosuvastatin Calcium	Rosuvastatin Calcium	107	suppressed
Omeprazole	Omeprazole	82	14
Mirtazapine	Mirtazapine	78	14
Divalproex Sodium	Divalproex Sodium	77	suppressed
Tamsulosin Hcl	Tamsulosin Hcl	75	suppressed
Metoprolol Succinate	Metoprolol Succinate	71	suppressed
Hydrochlorothiazide	Hydrochlorothiazide	66	suppressed
Donepezil Hcl	Donepezil Hcl	64	suppressed
Ipratropium-Albuterol	Ipratropium/Albuterol Sulfate	64	suppressed
Lorazepam	Lorazepam	64	25
Pantoprazole Sodium	Pantoprazole Sodium	63	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	63	12
Metoprolol Tartrate	Metoprolol Tartrate	62	suppressed
Sertraline Hcl	Sertraline Hcl	59	suppressed
Pravastatin Sodium	Pravastatin Sodium	55	suppressed
Fluvoxamine Maleate	Fluvoxamine Maleate	52	suppressed
Clopidogrel	Clopidogrel Bisulfate	49	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	45	16
Ropinirole Hcl	Ropinirole Hcl	45	suppressed
Ondansetron Odt	Ondansetron	43	20
Nystatin	Nystatin	42	11
Trazodone Hcl	Trazodone Hcl	40	suppressed
Montelukast Sodium	Montelukast Sodium	37	suppressed
Tramadol Hcl	Tramadol Hcl	37	12
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	36	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	36	suppressed
Hydralazine Hcl	Hydralazine Hcl	36	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	36	suppressed
Xarelto	Rivaroxaban	36	suppressed
Buspirone Hcl	Buspirone Hcl	35	suppressed
Nifedipine Er	Nifedipine	35	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	34	suppressed
Memantine Hcl	Memantine Hcl	33	suppressed
Silver Sulfadiazine	Silver Sulfadiazine	33	suppressed
Valsartan	Valsartan	32	suppressed
Nuedexta	Dextromethorphan Hbr/Quinidine	31	suppressed
Tresiba Flextouch U-100	Insulin Degludec	31	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	29	suppressed
Trintellix	Vortioxetine Hydrobromide	29	suppressed
Olanzapine	Olanzapine	28	suppressed
Glipizide	Glipizide	27	suppressed
Ketoconazole	Ketoconazole	27	suppressed
Levetiracetam	Levetiracetam	26	suppressed
Methenamine Hippurate	Methenamine Hippurate	26	suppressed
Baclofen	Baclofen	25	suppressed
Hydrocortisone	Hydrocortisone	25	suppressed
Lamotrigine	Lamotrigine	25	suppressed
Cephalexin	Cephalexin	24	13
Risperidone	Risperidone	24	suppressed
Clonazepam	Clonazepam	23	suppressed
Duloxetine Hcl	Duloxetine Hcl	23	suppressed
Latanoprost	Latanoprost	23	suppressed
Vascepa	Icosapent Ethyl	23	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	23	suppressed
Valacyclovir	Valacyclovir Hcl	22	suppressed
Verapamil Hcl	Verapamil Hcl	22	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	21	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	21	12
Flecainide Acetate	Flecainide Acetate	21	suppressed
Carbidopa-Levodopa	Carbidopa/Levodopa	20	suppressed
Lovastatin	Lovastatin	20	suppressed
Topiramate	Topiramate	20	suppressed
Trulicity	Dulaglutide	20	suppressed
Alendronate Sodium	Alendronate Sodium	19	suppressed
Atenolol-Chlorthalidone	Atenolol/Chlorthalidone	19	suppressed
Carbamazepine	Carbamazepine	19	suppressed
Dilt-Xr	Diltiazem Hcl	19	suppressed
Dexamethasone	Dexamethasone	18	suppressed
Fiasp	Insulin Aspart (Niacinamide)	18	suppressed
Fiasp Flextouch	Insulin Aspart (Niacinamide)	18	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	18	13
Sodium Chloride	0.9 % Sodium Chloride	18	suppressed
Budesonide Ec	Budesonide	17	suppressed
Calcium Acetate	Calcium Acetate	17	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	17	suppressed
Nyamyc	Nystatin	17	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	17	suppressed
Januvia	Sitagliptin Phosphate	16	suppressed
Midodrine Hcl	Midodrine Hcl	16	suppressed
Brimonidine Tartrate	Brimonidine Tartrate	15	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	15	suppressed
Insulin Lispro Kwikpen U-100	Insulin Lispro	15	suppressed
Lansoprazole	Lansoprazole	15	suppressed
Ondansetron Hcl	Ondansetron Hcl	15	12
Bupropion Xl	Bupropion Hcl	14	suppressed
Desipramine Hcl	Desipramine Hcl	14	suppressed
Fluconazole	Fluconazole	14	suppressed
Ibuprofen	Ibuprofen	13	suppressed
Lantus	Insulin Glargine,hum.Rec.Anlog	13	suppressed
Nebivolol Hcl	Nebivolol Hcl	13	suppressed
Rivastigmine	Rivastigmine	13	suppressed
Allopurinol	Allopurinol	12	suppressed
Cefdinir	Cefdinir	12	suppressed
Ertapenem	Ertapenem Sodium	12	suppressed
Morphine Sulfate	Morphine Sulfate	12	12
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	12	suppressed
Amiodarone Hcl	Amiodarone Hcl	11	suppressed
Digoxin	Digoxin	11	suppressed
Erythromycin	Erythromycin Base	11	suppressed
Famotidine	Famotidine	11	suppressed
Hydroxyurea	Hydroxyurea	11	suppressed
Levetiracetam Er	Levetiracetam	11	suppressed
Meropenem	Meropenem	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error